Structure Therapeutics(GPCR) - 2025 Q2 - Quarterly Results

Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025 Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestonesthrough at least 2027 Exhi ...